Physician profile
Christopher S Aou
NPI 1164422671
$1,117.22
in general payments reported to CMS, 2019-2025
14 companies · $218 in 2025
The $218 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $469 · 2020: $66.21 · 2022: $125 · 2024: $240 · 2025: $218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $458.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $457.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $208.49 | 2019-2020 | |
| Glaxosmithkline, LLC. | $134.02 | 2019-2024 | Arexvy |
| Idorsia Pharmaceuticals US INC | $124.68 | 2022 | |
| Mayne Pharma Commercial LLC | $121.37 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $121.37 | 2024 | Farxiga |
| Pfizer INC. | $108.40 | 2019 | |
| Dexcom, INC. | $96.25 | 2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $72.93 | 2019 | |
| Novo Nordisk INC | $36.38 | 2019 | |
| Abbvie INC. | $20.57 | 2019 | |
| Sanofi Pasteur INC. | $19.76 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $18.53 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.32 | 2019 | |
| Lilly USA, LLC | $16.15 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Aou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.